The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

Trial Profile

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin (Primary)
  • Indications Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 24 Feb 2017 Results assessing baseline characteristics and clinical outcomes of a non-valvular atrial fibrillation patient population, presented at the 42nd International Stroke Conference
    • 22 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top